Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

July 26, 2019July 26, 2019

Levels of Chemokines CXCL8, CXCL10 May Help Predict Risk for JIA, RA, Study Suggests

News

Blood levels of chemokines CXCL8 and CXCL10 — two signalling molecules— may help predict risk for juvenile idiopathic arthritis and rheumatoid arthritis, according to a study in a group ... Read more

July 9, 2019July 9, 2019

Adding Humira to Methotrexate Can Aid Vision and Help Avoid Uveitis Flares in JIA Children, Study Suggests

News

Adding Humira (adalimumab) to methotrexate lowers the risk of juvenile idiopathic arthritis-associated uveitis flares and helps to maintain visual acuity in children who do not respond to methotrexate alone, ... Read more

July 2, 2019July 2, 2019

Often Misdiagnosed, Adults with pJIA Have Distinct Clinical Features from Rheumatoid Arthritis Patients, Study Reports

News

Adults with polyarticular juvenile idiopathic arthritis have distinct clinical features from those with rheumatoid arthritis, with greater prevalence of tumor necrosis factor inhibitors, a study reports. The study, “Comparison ... Read more

June 14, 2019June 14, 2019

Dose, Duration of Methotrexate Treatment May Be Linked to Lung Impairments in JIA Patients

News

Treatment with methotrexate, an immunosuppressive therapy, may be linked to a decline in lung function in children with juvenile idiopathic arthritis (JIA), a study suggests. The study, “Lung function ... Read more

May 7, 2019May 7, 2019

Eticovo, a Biosimilar of Enbrel, Approved by FDA for Polyarticular JIA Patients Ages 2 and Older

News

Eticovo (etanercept-ykro), a biosimilar of Enbrel (etanercept), has been approved by the U.S. Food and Drug Administration (FDA) as a therapy for lessening symptoms in children ages two and older ... Read more

April 5, 2019April 5, 2019

Fertility Treatments Do Not Affect Child’s Risk for Developing Juvenile Idiopathic Arthritis, Large Study Finds

News

Children who were conceived by women using fertility treatments do not show an increased risk for juvenile idiopathic arthritis (JIA), a large Danish population study reports. The study, “Risk ... Read more

January 18, 2019January 18, 2019

Walking Problems May Persist in Children Even as Inflammation Eases Over Time, Study Finds

News

Knee and ankle joint inflammation and walking difficulties in children and adolescents with juvenile idiopathic arthritis (JIA) tends to decrease and stabilize in the first five years after diagnosis, ... Read more

January 15, 2019January 15, 2019

Boys with Early JIA Have Greater Deficit of IGF-1 than Girls, Study Shows

News

Boys with early juvenile idiopathic arthritis (JIA) have lower levels of insulin-like growth factor 1, a growth hormone, compared to age-matched girls in the same stage of early disease, ... Read more

September 7, 2018September 7, 2018

Humira’s Safety in Children With JA, Other Diseases Comparable to That in Adults, Study Suggests

News

The safety profile of Humira (adalimumab) in children with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis, and Crohn’s disease is similar to that in adults, a large analysis of ... Read more

August 6, 2018August 6, 2018

Naproxen-based Combo May Help Reduce Risk of Gastric Ulcers in JIA Teens, Phase 4 Trial Shows

News

Results from a six-month, Phase 4 trial support a combination therapy of the anti-inflammatory naproxen together with an immediate-release form of esomeprazole to reduce the risk of gastric ulcers ... Read more

Pin It on Pinterest